<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745794</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0519</org_study_id>
    <secondary_id>NCI-2018-02182</secondary_id>
    <secondary_id>2018-0519</secondary_id>
    <nct_id>NCT03745794</nct_id>
  </id_info>
  <brief_title>Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery</brief_title>
  <official_title>Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Pancreatectomy (&quot;RESQU-BLOCK&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how an additional anesthetic nerve block, called a quadratus&#xD;
      lumborum block, works to reduce the need for opioids in patients after pancreatic surgery.&#xD;
      Giving an additional regional anesthetic after surgery may hasten the weaning process, reduce&#xD;
      the need for opioid medications upon discharge, and reduce the risk of opioid dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To use a phase II randomized controlled trial to compare the intervention of a second&#xD;
      regional anesthetic block (quadratus lumborum [QL] block) versus usual care (single&#xD;
      intraoperative QL block) to increase the proportion of opioid-free pancreatic cancer&#xD;
      survivors at discharge after potentially curative surgery.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM 1: Patients undergo QL block before surgery and receive standard of care multimodal pain&#xD;
      control after surgery.&#xD;
&#xD;
      ARM 2: Patients undergo QL block before surgery and receive multimodal pain control. Patients&#xD;
      then undergo a second QL block on day 4 after surgery and continue to receive standard of&#xD;
      care.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 month, 3 months, 6 months,&#xD;
      and 1 year after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of opioid-free patients between the two arms</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Will perform Chi-squared test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total inpatient oral morphine equivalents (OME)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital cost</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score assessed by MD Anderson Symptom Inventory-Gastrointestinal (MDASI-GI)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain prescription dosage/size</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with initial discharge prescription dosage/size total OME &lt; 200 mg</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients using opioids</measure>
    <time_frame>At 30 days after surgery</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDASI-GI in clinic visits</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients using opioids</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total OME for first 30 days and first 90 days (inpatient + outpatient)</measure>
    <time_frame>At 30 and 90 days</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients and family free of opioid use</measure>
    <time_frame>At 6 months and 1 year</time_frame>
    <description>Two sample t-test or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Given standard of care</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadratus Lumborum Block</intervention_name>
    <description>Undergo QL block</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>QL Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (QL block, standard of care)</arm_group_label>
    <arm_group_label>Arm II (second QL block)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective open pancreatic resection for potentially curative intent&#xD;
             (pancreaticoduodenectomy or distal pancreatectomy) who would otherwise be treated with&#xD;
             QL block + IV-PCA converted to oral pain meds (non-narcotic bundle + opioid pain&#xD;
             pill).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with current or past substance (drug or alcohol) abuse disorder.&#xD;
&#xD;
          -  Laparoscopic or minimally invasive surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Wei D Tzeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

